Journal of Antimicrobial Chemotherapy (2001) 48, 33-42
© 2001 The British Society for Antimicrobial Chemotherapy
Supplement |
Activity of the ketolide antibacterial telithromycin against typical community-acquired respiratory pathogens
a GR Micro Ltd, 7–9 William Road, London NW1 3ER, UK; b Health Sciences Center, Winnipeg, Canada
Abstract
Community-acquired respiratory tract infections (RTIs) are among the most prevalent infectious diseases in the developed world. They cause considerable morbidity, resulting in a major impact on public health both clinically and socioeconomically. The bacterial pathogens most commonly associated with community-acquired RTIs are Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis, with Streptococcus pyogenes predominating in pharyngitis. Over the past years, each of these pathogens has developed mechanisms to evade susceptibility to antibacterials, leading to an alarming global increase in antibacterial resistance among these pathogens. There is great concern that currently available antibacterials are insufficient to treat community-acquired RTIs and there is an urgent requirement for new agents with activity against all strains of common community-acquired RTI pathogens. Telithromycin (HMR 3647) belongs to a new family of antibacterials, the ketolides, and has been specifically designed for the treatment of community-acquired RTIs. This review covers the potent in vitro activity of telithromycin against the most common community-acquired RTI pathogens compared with other currently available antimicrobial agents.
Notes
* Corresponding author. Tel: +44-20-7388-7320; Fax: +44-20-7388-8514; E-mail: d.felmingham{at}grmicro.co.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Gattringer, E. Urbauer, F. Traunmuller, M. Zeitlinger, P. Dehghanyar, P. Zeleny, W. Graninger, M. Muller, and C. Joukhadar Pharmacokinetics of Telithromycin in Plasma and Soft Tissues after Single-Dose Administration to Healthy Volunteers Antimicrob. Agents Chemother., December 1, 2004; 48(12): 4650 - 4653. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Muller-Serieys, J. Andrews, F. Vacheron, and C. Cantalloube Tissue kinetics of telithromycin, the first ketolide antibacterial J. Antimicrob. Chemother., February 1, 2004; 53(2): 149 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Buxbaum, S. Forsthuber, W. Graninger, and A. Georgopoulos Comparative activity of telithromycin against typical community-acquired respiratory pathogens J. Antimicrob. Chemother., September 1, 2003; 52(3): 371 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Leclercq and P. Courvalin Resistance to Macrolides and Related Antibiotics in Streptococcus pneumoniae Antimicrob. Agents Chemother., September 1, 2002; 46(9): 2727 - 2734. [Full Text] [PDF]
|
|